Cargando…

In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors

Cisplatin reacts with DNA and thereby likely generates a characteristic pattern of somatic mutations, called a mutational signature. Despite widespread use of cisplatin in cancer treatment and its role in contributing to secondary malignancies, its mutational signature has not been delineated. We hy...

Descripción completa

Detalles Bibliográficos
Autores principales: Boot, Arnoud, Huang, Mi Ni, Ng, Alvin W.T., Ho, Szu-Chi, Lim, Jing Quan, Kawakami, Yoshiiku, Chayama, Kazuaki, Teh, Bin Tean, Nakagawa, Hidewaki, Rozen, Steven G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932606/
https://www.ncbi.nlm.nih.gov/pubmed/29632087
http://dx.doi.org/10.1101/gr.230219.117
_version_ 1783319847458832384
author Boot, Arnoud
Huang, Mi Ni
Ng, Alvin W.T.
Ho, Szu-Chi
Lim, Jing Quan
Kawakami, Yoshiiku
Chayama, Kazuaki
Teh, Bin Tean
Nakagawa, Hidewaki
Rozen, Steven G.
author_facet Boot, Arnoud
Huang, Mi Ni
Ng, Alvin W.T.
Ho, Szu-Chi
Lim, Jing Quan
Kawakami, Yoshiiku
Chayama, Kazuaki
Teh, Bin Tean
Nakagawa, Hidewaki
Rozen, Steven G.
author_sort Boot, Arnoud
collection PubMed
description Cisplatin reacts with DNA and thereby likely generates a characteristic pattern of somatic mutations, called a mutational signature. Despite widespread use of cisplatin in cancer treatment and its role in contributing to secondary malignancies, its mutational signature has not been delineated. We hypothesize that cisplatin's mutational signature can serve as a biomarker to identify cisplatin mutagenesis in suspected secondary malignancies. Knowledge of which tissues are at risk of developing cisplatin-induced secondary malignancies could lead to guidelines for noninvasive monitoring for secondary malignancies after cisplatin chemotherapy. We performed whole genome sequencing of 10 independent clones of cisplatin-exposed MCF-10A and HepG2 cells and delineated the patterns of single and dinucleotide mutations in terms of flanking sequence, transcription strand bias, and other characteristics. We used the mSigAct signature presence test and nonnegative matrix factorization to search for cisplatin mutagenesis in hepatocellular carcinomas and esophageal adenocarcinomas. All clones showed highly consistent patterns of single and dinucleotide substitutions. The proportion of dinucleotide substitutions was high: 8.1% of single nucleotide substitutions were part of dinucleotide substitutions, presumably due to cisplatin's propensity to form intra- and interstrand crosslinks between purine bases in DNA. We identified likely cisplatin exposure in nine hepatocellular carcinomas and three esophageal adenocarcinomas. All hepatocellular carcinomas for which clinical data were available and all esophageal cancers indeed had histories of cisplatin treatment. We experimentally delineated the single and dinucleotide mutational signature of cisplatin. This signature enabled us to detect previous cisplatin exposure in human hepatocellular carcinomas and esophageal adenocarcinomas with high confidence.
format Online
Article
Text
id pubmed-5932606
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Cold Spring Harbor Laboratory Press
record_format MEDLINE/PubMed
spelling pubmed-59326062018-11-01 In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors Boot, Arnoud Huang, Mi Ni Ng, Alvin W.T. Ho, Szu-Chi Lim, Jing Quan Kawakami, Yoshiiku Chayama, Kazuaki Teh, Bin Tean Nakagawa, Hidewaki Rozen, Steven G. Genome Res Research Cisplatin reacts with DNA and thereby likely generates a characteristic pattern of somatic mutations, called a mutational signature. Despite widespread use of cisplatin in cancer treatment and its role in contributing to secondary malignancies, its mutational signature has not been delineated. We hypothesize that cisplatin's mutational signature can serve as a biomarker to identify cisplatin mutagenesis in suspected secondary malignancies. Knowledge of which tissues are at risk of developing cisplatin-induced secondary malignancies could lead to guidelines for noninvasive monitoring for secondary malignancies after cisplatin chemotherapy. We performed whole genome sequencing of 10 independent clones of cisplatin-exposed MCF-10A and HepG2 cells and delineated the patterns of single and dinucleotide mutations in terms of flanking sequence, transcription strand bias, and other characteristics. We used the mSigAct signature presence test and nonnegative matrix factorization to search for cisplatin mutagenesis in hepatocellular carcinomas and esophageal adenocarcinomas. All clones showed highly consistent patterns of single and dinucleotide substitutions. The proportion of dinucleotide substitutions was high: 8.1% of single nucleotide substitutions were part of dinucleotide substitutions, presumably due to cisplatin's propensity to form intra- and interstrand crosslinks between purine bases in DNA. We identified likely cisplatin exposure in nine hepatocellular carcinomas and three esophageal adenocarcinomas. All hepatocellular carcinomas for which clinical data were available and all esophageal cancers indeed had histories of cisplatin treatment. We experimentally delineated the single and dinucleotide mutational signature of cisplatin. This signature enabled us to detect previous cisplatin exposure in human hepatocellular carcinomas and esophageal adenocarcinomas with high confidence. Cold Spring Harbor Laboratory Press 2018-05 /pmc/articles/PMC5932606/ /pubmed/29632087 http://dx.doi.org/10.1101/gr.230219.117 Text en © 2018 Boot et al.; Published by Cold Spring Harbor Laboratory Press http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genome.cshlp.org/site/misc/terms.xhtml). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Research
Boot, Arnoud
Huang, Mi Ni
Ng, Alvin W.T.
Ho, Szu-Chi
Lim, Jing Quan
Kawakami, Yoshiiku
Chayama, Kazuaki
Teh, Bin Tean
Nakagawa, Hidewaki
Rozen, Steven G.
In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors
title In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors
title_full In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors
title_fullStr In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors
title_full_unstemmed In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors
title_short In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors
title_sort in-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932606/
https://www.ncbi.nlm.nih.gov/pubmed/29632087
http://dx.doi.org/10.1101/gr.230219.117
work_keys_str_mv AT bootarnoud indepthcharacterizationofthecisplatinmutationalsignatureinhumancelllinesandinesophagealandlivertumors
AT huangmini indepthcharacterizationofthecisplatinmutationalsignatureinhumancelllinesandinesophagealandlivertumors
AT ngalvinwt indepthcharacterizationofthecisplatinmutationalsignatureinhumancelllinesandinesophagealandlivertumors
AT hoszuchi indepthcharacterizationofthecisplatinmutationalsignatureinhumancelllinesandinesophagealandlivertumors
AT limjingquan indepthcharacterizationofthecisplatinmutationalsignatureinhumancelllinesandinesophagealandlivertumors
AT kawakamiyoshiiku indepthcharacterizationofthecisplatinmutationalsignatureinhumancelllinesandinesophagealandlivertumors
AT chayamakazuaki indepthcharacterizationofthecisplatinmutationalsignatureinhumancelllinesandinesophagealandlivertumors
AT tehbintean indepthcharacterizationofthecisplatinmutationalsignatureinhumancelllinesandinesophagealandlivertumors
AT nakagawahidewaki indepthcharacterizationofthecisplatinmutationalsignatureinhumancelllinesandinesophagealandlivertumors
AT rozensteveng indepthcharacterizationofthecisplatinmutationalsignatureinhumancelllinesandinesophagealandlivertumors